NYSE: CRLCharles River Laboratories
Charles River agrees to acquire Frontage bioanalysis unit for $470 million
- US stocks
- Mergers & acquisitions
- Health Care

Charles River Laboratories (NYSE: CRL) signed definitive agreements to acquire the bioanalysis and DMPK operations of Frontage Holdings Corporation in Exton, Pennsylvania for $470 million in cash, it said on 9 Nov 2026. Frontage is listed in Hong Kong. The deal is being done with a consortium that includes Tigermed and Dr. Song Li, which will first take Frontage private.
Key highlights
- Cash price: $470.0 million, subject to customary closing adjustments
- Additional payments: up to $75.0 million, tied to future performance
- Frontage 2025 revenue: $256.7 million; the acquired units were about 40% of it
- Expected closing: first half of 2027
The deal in numbers
| Item | Detail |
|---|---|
| Buyer | Charles River Laboratories |
| Business being acquired | Bioanalysis and DMPK operations of Frontage Holdings, in Exton, Pennsylvania |
| Cash price | $470.0 million, subject to customary closing adjustments |
| Additional payments | Up to $75.0 million, contingent on future performance of the acquired businesses |
| Financing | Charles River's credit facility and available cash |
| Sites and staff | Two Exton sites of about 150,000 square feet and about 340 employees |
| Expected closing | First half of 2027, subject to shareholder and regulatory approvals |
| Reporting segment | DSA segment |
Frontage is being taken private by a consortium
Charles River is buying together with Frontage's controlling shareholder, Tigermed, and its chairman, Dr. Song Li. The three have set up an acquisition vehicle to take Frontage private through a court-sanctioned scheme of arrangement, which would withdraw its Hong Kong listing. Afterwards Frontage's businesses are to be separated, with Charles River keeping the bioanalysis and DMPK operations.
Completion needs resolutions at a Tigermed general meeting, regulatory approvals, Frontage shareholder approval and sanction by the Grand Court of the Cayman Islands. Tigermed, Dr. Song Li and trusts he controls have each committed to back the transaction.
Charles River says the deal adds clinical bioanalysis scale
The company puts clinical-phase testing at about 15% of its bioanalysis revenue, and biologics and complex modalities at about 75%. It said most of Frontage's 2025 bioanalysis revenue came from clinical development.
The company expects the bioanalysis sector to grow from $6.00 billion in 2026 to $8.00 billion to $9.00 billion in 2031, which it describes as annual growth of 6% to 8%. It expects revenue of the acquired businesses to grow at that sector rate over the next five years.
Earnings and financing
The company says it expects the deal to leave non-GAAP earnings per share unchanged in 2027 and to add to it afterwards. It describes non-GAAP earnings per share as its own measure, which excludes acquisition costs, mainly amortization of intangible assets, advisory fees and certain integration costs.
The acquisition and related fees are to be financed through the credit facility and available cash.
What the Charles River deal means for CRL shareholders
The company says the deal adds Frontage's bioanalysis and DMPK operations, which it will report in its DSA segment. The filing does not give the revenue or profit of the acquired businesses in dollars, a GAAP earnings effect, or how much of the up to $75.0 million is expected to be paid.
The next step is the scheme document, which is to be sent to Frontage shareholders, and the approvals listed above.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.
